Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Accured Expenses: 2021-2025

Historic Change in Accured Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $8.4 million.

  • Kiniksa Pharmaceuticals International's Change in Accured Expenses fell 22.49% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year decrease of 24.09%. This contributed to the annual value of $43.7 million for FY2024, which is 158.14% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Change in Accured Expenses stood at $8.4 million for Q3 2025, which was down 36.11% from $13.1 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Change in Accured Expenses high stood at $18.7 million for Q2 2024, and its period low was -$10.6 million during Q1 2023.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Change in Accured Expenses averaged around $7.1 million, with its median value being $8.4 million (2025).
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Change in Accured Expenses slumped by 456.87% in 2022 and then surged by 345.95% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Change in Accured Expenses (Quarterly) stood at $10.0 million in 2021, then tumbled by 137.74% to -$3.8 million in 2022, then surged by 239.44% to $5.3 million in 2023, then skyrocketed by 107.96% to $11.0 million in 2024, then decreased by 22.49% to $8.4 million in 2025.
  • Its last three reported values are $8.4 million in Q3 2025, $13.1 million for Q2 2025, and -$3.6 million during Q1 2025.